387 INVITED PI3K Pathway Inhibitors: What Have we Achieved and Future Directions
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2011 |
---|---|
Erschienen: |
2011 |
Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
---|---|
Enthalten in: |
The European journal of cancer / A - 47(2011), 1, SUPPL vom: Sept., Seite 8-9 |
Beteiligte Personen: |
Tabernero, J. [VerfasserIn] |
---|
RVK: |
---|
Umfang: |
1 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
OLC1879935929 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC1879935929 | ||
003 | DE-627 | ||
005 | 20230712184108.0 | ||
007 | tu | ||
008 | 111004s2011 xx ||||| 00| ||und c | ||
028 | 5 | 2 | |a sw110930_1 |
035 | |a (DE-627)OLC1879935929 | ||
035 | |a (DE-599)GBVOLC1879935929 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
082 | 0 | 4 | |a 610 |
084 | |a XA 42017 |q AVZ |2 rvk | ||
100 | 1 | |a Tabernero, J. |e verfasserin |4 aut | |
245 | 1 | 0 | |a 387 INVITED PI3K Pathway Inhibitors: What Have we Achieved and Future Directions |
264 | 1 | |c 2011 | |
300 | |a 1 | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
700 | 1 | |a Dienstmann, R. |4 oth | |
700 | 1 | |a Cervantes, A. |4 oth | |
700 | 1 | |a Brafia, I. |4 oth | |
700 | 1 | |a Alsina, M. |4 oth | |
700 | 1 | |a Rodon, J. |4 oth | |
773 | 0 | 8 | |i Enthalten in |t The European journal of cancer / A |d Oxford [u.a.] : Pergamon Press, 1992 |g 47(2011), 1, SUPPL vom: Sept., Seite 8-9 |w (DE-627)131110047 |w (DE-600)1120460-6 |w (DE-576)03274031X |x 0959-8049 |7 nnns |
773 | 1 | 8 | |g volume:47 |g year:2011 |g number:1 |g month:09 |g supplement:SUPPL |g pages:8-9 |g extent:1 |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
936 | r | v | |a XA 42017 |
951 | |a AR | ||
952 | |d 47 |j 2011 |e 1 |c 9 |f SUPPL |h 8-9 |g 1 |